A look at the effectiveness of the release of active antivirals in treatment of influenza and ARVI in the light of evidence-based medicine

Cover Page

Cite item

Full Text

Abstract

The problem of treatment and prophylaxis of acute respiratory viral infections (ARVI) is interdisciplinary and covers medical, social and economic aspects. The high relevance of the problem is determined by the prevalence of infections themselves, high sensitivity to them patients of all age categories, a significant rate of complications and exacerbations of several chronic diseases, especially in patients at risk. The lack of specific methods of prevention and treatment of ARVI, its non-influenza etiology, limited range of drugs for antiviral therapy in this group of medicines determine the need for a thorough analysis of the efficacy and safety of existing drugs with the position of evidence-based medicine. Attention of authors was attracted by a group of innovative domestic antivirals, established on the basis of antibodies to interferon-g release in a human-active form. This work is carried out with the purpose of concentration and systematization of information on the results of the preclinical assessment of antiviral activity of Ergoferon, Anaferon Kids and Anaferon, as well as data from clinical studies of these drugs in acute respiratory viral infections in children and adults. It uses search-analytical method for processing information sources published in specialized medical journals and are freely available in printed and electronic form on the Internet. The work is a brief literature review, which presents evidence of antiviral activity of Ergoferon, Anaferon Kids and Anaferon, current understanding of the mechanism of action of drugs, based on the data of the complex scientific and experimental studies on the molecular level. Also, review the results of clinical trials, which, according to the authors, with a high degree of evidence demonstrating the therapeutic efficacy and Ergoferon, as well as Anaferon Kids in the treatment of ARVI. Proofs of comparability of treatment of the antiviral activity of these drugs with ostamyvirum during influenza treatment in children and adults.

About the authors

O. I Afanasyeva

Research Institute of Influenza of the Ministry of Health of Russian Federation

Email: CHalyabiGA@materimedica.ru
д-р мед. наук, проф., зав. отд. респираторных вирусных инфекций у детей ФГБУ НИИ гриппа 197376, Russian Federation, Saint Petersburg, ul. Professora Popova, d. 15/17

E. V Esaulenko

Saint Petersburg State Pediatric Medical University of the Ministry of Health of the Russian Federation

д-р мед. наук, проф., зав. каф. инфекционных болезней взрослых и эпидемиологии ГБОУ ВПО СПбГПМУ 194100, Russian Federation, Saint Petersburg, Litovskaja ul., d. 2

References

  1. http://www.rospotrebnadzor.ru/deyatelnost/epidemiological-surveillance/
  2. World Health Organization. Influenza update, 15 June 2015. http://www.who.int/influenza/surveillance_monitoring/updates/latest_update_GIP_surveillance/en/
  3. Influenza Activity - United States, 2014-15 Season and Composition of the 2015-16 Influenza Vaccine. Morbidity and Mortality Weekly Report (MMWR). http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6421a5.htm
  4. Calatayud L, Lackenby A, Reynolds A et al. Oseltamivir-Resistant Pandemic (H1N1) 2009 Virus Infection in England and Scotland, 2009-2010. Emerg Infect Dis 2011; 17 (10): 1807-15.
  5. Storms A.D, Gubareva L.V, Su Su et al. Oseltamivir-Resistant Pandemic (H1N1)2009 Virus Infections, United States, 2010-11. Emerg Infect Dis 2012; 18 (2). DOI: http://dx.doi.org/10.3201/eid1802.111466
  6. Jefferson T, Jones M, Doshi P et al. Neuraminidase inhibitors for preventing and treating influenza in healthy adults: a Cochrane review. Cochrane Database Syst Rev 2014; 4: CD008965.
  7. Эпштейн О.И. Релиз - активность от феномена до создания новых лекарственных средств. Бюл. экспериментальной биологии и медицины. 2012; 154: 62-7.
  8. Эпштейн О.И. Феномен релиз - активности и гипотеза «пространственного» гомеостаза. Успехи физиологических наук. 2013; 44: 54-76.
  9. Тарасов С.А., Качанова М.В., Горбунов Е.А. и др. Анаферон - эффективное средство для лечения и профилактики широкого спектра инфекционных заболеваний. Вестн. международной академии наук (русская секция). 2010; 23-7.
  10. Tarasov S.A, Zarubaev V.V, Gorbunov E.A et al. Activity of ultra - low doses of antibodies to gamma - interferon against lethal influenza A(H1N1)2009 virus infection in mice. Antiviral Res 2012; 93: 219-24.
  11. Ахмадуллина Р. Р. Особенности эпидемического процесса гриппа и гриппоподобных заболеваний (на модели Московской области). Автореф. дисс. ... канд. мед. наук. М., 2006.
  12. Каира А.Н., Соломай Т.В., Королькова Е.А. Применение препарата «Анаферон» для профилактики острых респираторных заболеваний. Санитарный врач. 2014; 7: 54-8.

Copyright (c) 2016 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies